Loading
In tumours with faulty DNA repair, adding olaparib to bevacizumab maintenance roughly doubled progression-free time and improved survival.
In newly diagnosed advanced ovarian cancer with homologous recombination deficiency, adding the PARP inhibitor olaparib to bevacizumab maintenance is a combination pairing that markedly prolonged progression-free time and improved overall survival in the phase 3 PAOLA-1 / ENGOT-ov25 trial, with no benefit seen in HRD-negative tumours. The mechanistic rationale is that anti-angiogenic hypoxia may push tumour cells into HRD-like states and greater dependence on PARP, and the two agents have non-overlapping toxicity. The combination was approved in 2020. Because the benefit was confined to the HRD-positive subgroup, the pairing made HRD testing a routine first-line decision in ovarian cancer.
Shares Platinum-sensitive ovarian cancer, PARP, Olaparib, Bevacizumab.
Shares PAOLA-1 / ENGOT-ov25, VEGF / VEGFR, PARP, Olaparib.
Shares Platinum-sensitive ovarian cancer, Olaparib, Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, Olaparib, Ovarian cancer.
Shares Olaparib, Bevacizumab, Ovarian cancer.
Shares Homologous recombination deficiency (HRD), PARP, Olaparib, Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, Olaparib, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/